The efficacy of twice-weekly, fixed-dose combination calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam for the long-term maintenance of plaque psoriasis was supported in results from a clinical trial published in the Journal of the American Academy of Dermatology.

Compared with patients who received placebo, those who used Cal/BD were more likely to remain in remission during 1 year of follow-up. The foam was well-tolerated, with few serious adverse events reported.

Read the full article at